{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:33:26Z","timestamp":1791506006287,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T00:00:00Z","timestamp":1545004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007857","name":"Stiftelsen Konung Gustaf V:s 80-\u00e5rsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Reumatikerf\u00f6rbundet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ebiom.2018.12.035","type":"journal-article","created":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T00:06:13Z","timestamp":1545782773000},"page":"517-527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":138,"special_numbering":"C","title":["B cell alterations during BAFF inhibition with belimumab in SLE"],"prefix":"10.1016","volume":"40","author":[{"given":"Daniel","family":"Ramsk\u00f6ld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Parodis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadepally","family":"Lakshmikanth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Sippl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Khademi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agneta","family":"Zickert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarom\u00edr","family":"Mike\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnane","family":"Achour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Amara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-5219","authenticated-orcid":false,"given":"Fredrik","family":"Piehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Brodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Gunnarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9251-8082","authenticated-orcid":false,"given":"Vivianne","family":"Malmstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ebiom.2018.12.035_bb0005","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/rheumatology\/kep062","article-title":"Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10\u202fyears","volume":"48","author":"Chambers","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ebiom.2018.12.035_bb0010","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.30277","article-title":"Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China","volume":"63","author":"Mok","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.ebiom.2018.12.035_bb0015","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.3899\/jrheum.080214","article-title":"Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus","volume":"35","author":"Urowitz","year":"2008","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.ebiom.2018.12.035_bb0020","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1517\/14656566.2014.894976","article-title":"Molecular abnormalities of the B cell in systemic lupus erythematosus are candidates for functional inhibition treatments","volume":"15","author":"Liossis","year":"2014","journal-title":"Expert Opin Pharmacother"},{"issue":"7539","key":"10.1016\/j.ebiom.2018.12.035_bb0025","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature13835","article-title":"Genetic and epigenetic fine mapping of causal autoimmune disease variants","volume":"518","author":"Farh","year":"2015","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ebiom.2018.12.035_bb0030","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1002\/art.11354","article-title":"B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations","volume":"48","author":"Stohl","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ebiom.2018.12.035_bb0035","doi-asserted-by":"crossref","first-page":"e000061","DOI":"10.1136\/lupus-2014-000061","article-title":"Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy","volume":"2","author":"Parodis","year":"2015","journal-title":"Lupus Sci Med"},{"issue":"9767","key":"10.1016\/j.ebiom.2018.12.035_bb0040","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ebiom.2018.12.035_bb0045","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.ebiom.2018.12.035_bb0050","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"van Vollenhoven","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ebiom.2018.12.035_bb0055","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.34400","article-title":"Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ebiom.2018.12.035_bb0060","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/art.27189","article-title":"Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study","volume":"62","author":"Jacobi","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.ebiom.2018.12.035_bb0065","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.ebiom.2018.12.035_bb0070","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.ebiom.2018.12.035_bb0075","first-page":"447","article-title":"The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus","volume":"86","author":"Hay","year":"1993","journal-title":"Q J Med"},{"issue":"9","key":"10.1016\/j.ebiom.2018.12.035_bb0080","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1191\/096120300672904669","article-title":"From BILAG to BLIPS\u2014disease activity assessment in lupus past, present and future","volume":"9","author":"Isenberg","year":"2000","journal-title":"Lupus"},{"issue":"24","key":"10.1016\/j.ebiom.2018.12.035_bb0085","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ebiom.2018.12.035_bb0090","doi-asserted-by":"crossref","first-page":"953","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00004","article-title":"The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial","volume":"142","author":"Buyon","year":"2005","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.ebiom.2018.12.035_bb0095","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.24698","article-title":"Novel evidence-based systemic lupus erythematosus responder index","volume":"61","author":"Furie","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.ebiom.2018.12.035_bb0100","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ebiom.2018.12.035_bb0105","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/cyto.a.22271","article-title":"Normalization of mass cytometry data with bead standards","volume":"83","author":"Finck","year":"2013","journal-title":"Cytometry A"},{"issue":"8","key":"10.1016\/j.ebiom.2018.12.035_bb0110","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nri1416","article-title":"Seventeen-colour flow cytometry: unravelling the immune system","volume":"4","author":"Perfetto","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ebiom.2018.12.035_bb0115","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1749-6632.1975.tb29197.x","article-title":"Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique","volume":"254","author":"Aarden","year":"1975","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.ebiom.2018.12.035_bb0120","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1073\/pnas.1321405111","article-title":"Automatic classification of cellular expression by nonlinear stochastic embedding (ACCENSE)","volume":"111","author":"Shekhar","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.ebiom.2018.12.035_bb0125","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cell.2015.05.047","article-title":"Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis","volume":"162","author":"Levine","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ebiom.2018.12.035_bb0130","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1182\/blood-2011-01-331462","article-title":"Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c(+) B-cell population is important for the development of autoimmunity","volume":"118","author":"Rubtsov","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ebiom.2018.12.035_bb0135","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.4049\/jimmunol.1501209","article-title":"Age-associated B cells: a T-bet-dependent effector with roles in protective and pathogenic immunity","volume":"195","author":"Rubtsova","year":"2015","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2018.12.035_bb0140","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/s41467-018-03750-7","article-title":"IL-21 drives expansion and plasma cell differentiation of autoreactive CD11c(hi)T-bet(+) B cells in SLE","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.ebiom.2018.12.035_bb0145","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1182\/blood-2002-07-2103","article-title":"Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells","volume":"101","author":"Brenchley","year":"2003","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.ebiom.2018.12.035_bb0150","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2010-04-282301","article-title":"CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset","volume":"116","author":"Lopez-Verges","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ebiom.2018.12.035_bb0155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1189\/jlb.0809566","article-title":"CD57+ T lymphocytes and functional immune deficiency","volume":"87","author":"Focosi","year":"2010","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.ebiom.2018.12.035_bb0160","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3389\/fimmu.2013.00422","article-title":"Functional significance of CD57 expression on human NK cells and relevance to disease","volume":"4","author":"Nielsen","year":"2013","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2018.12.035_bb0165","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nri.2017.150","article-title":"Science not art: statistically sound methods for identifying subsets in multi-dimensional flow and mass cytometry data sets","volume":"18","author":"Orlova","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.ebiom.2018.12.035_bb0170","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ebiom.2018.12.035_bb0175","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3389\/fimmu.2012.00302","article-title":"Advances in human B cell phenotypic profiling","volume":"3","author":"Kaminski","year":"2012","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.ebiom.2018.12.035_bb0180","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00262-016-1803-z","article-title":"CD57 in human natural killer cells and T-lymphocytes","volume":"65","author":"Kared","year":"2016","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"10.1016\/j.ebiom.2018.12.035_bb0185","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1182\/blood.V89.5.1483","article-title":"A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation","volume":"89","author":"Delsol","year":"1997","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ebiom.2018.12.035_bb0190","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/08880010490501105","article-title":"Acute lymphoblastic leukemia with coexpression of CD56 and CD57: case report","volume":"21","author":"Matsubara","year":"2004","journal-title":"Pediatr Hematol Oncol"},{"issue":"3","key":"10.1016\/j.ebiom.2018.12.035_bb0195","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/modpathol.3800742","article-title":"ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature","volume":"20","author":"Reichard","year":"2007","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.ebiom.2018.12.035_bb0200","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/modpathol.2009.106","article-title":"Diffuse blastoid B-cell lymphoma: a histologically aggressive variant of t(14;18)-negative follicular lymphoma","volume":"22","author":"Chiu","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ebiom.2018.12.035_bb0205","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/brain\/awq386","article-title":"Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway","volume":"134","author":"Linker","year":"2011","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.ebiom.2018.12.035_bb0210","doi-asserted-by":"crossref","first-page":"691","DOI":"10.4049\/jimmunol.1601649","article-title":"Dimethyl fumarate treatment mediates an anti-inflammatory shift in B cell subsets of patients with multiple sclerosis","volume":"198","author":"Li","year":"2017","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.ebiom.2018.12.035_bb0215","doi-asserted-by":"crossref","first-page":"R167","DOI":"10.1186\/ar2076","article-title":"Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"8","author":"Vallerskog","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.ebiom.2018.12.035_bb0220","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.21650","article-title":"Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.ebiom.2018.12.035_bb0225","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.autrev.2017.02.005","article-title":"Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus","volume":"16","author":"Parodis","year":"2017","journal-title":"Autoimmun Rev"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396418306121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396418306121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:51:44Z","timestamp":1762455104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396418306121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":45,"alternative-id":["S2352396418306121"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2018.12.035","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B cell alterations during BAFF inhibition with belimumab in SLE","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2018.12.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}